X-pand into the **Future**

Corporate Action Information

Issue Date: 21 November 2018

Effective Date: tba

Contact: Derivatives Trading Operations, Tel. +49-69-211-1 12 10

Corporate Action	**Demerger / Name change**
Company	**Novartis**
ISIN	**CH0012005267**
Rules & Regulations	Contract Specifications for Futures Contracts and Options Contracts at Eurex Deutschland, section(s) 1.6.7 (8), 1.13.8 (9), 2.6.10.1 (8)
Options contracts on stocks	NOVN/NOVE/NOW1/2/4/5
Futures contracts on stocks	NOVF
Futures contracts on dividends of stocks	N2OV

The company Novartis has announced a planned spinoff of its eye care business as an independent company under the name Alcon. Shareholders of Novartis will receive Alcon share pro rata to their respective Novartis holdings.

More information about this transaction is available on the company`s website under www.Novartis.com.

The Spinoff will result in an adjustment of the above mentioned contracts.

eurex

Eurex Deutschland
Börsenplatz 4
60313 Frankfurt/Main
Mailing adress:
60485 Frankfurt/Main
Germany

T +49-69-211-1 17 00
F +49-69-211-1 17 01
eurextrading@
eurexchange.com
Internet:
www.eurexchange.com

Management Board::
Thomas Book, Erik Tim Müller,
Michael Peters, Randolf Roth

ARBN: 101 013 361

Procedure

Basket Method

- Effective day for the spinoff: tba
- As of the effective day the current underlying will be replaced by a Basket containing one Novartis share und Alcan shares respective to the subscription ratio determined by Novartis

Options

- As of the effective day, the Novartis-options reflect a basket containing one Novartis-share and a number of Alcon-shares, which reflects the subscription ratio.
- The ISIN, the product code and the name of the current Novartis options will change in Eurex Exchange`s T7. Details will follow in good time.
- The strike prices and contract size remains unchanged
- As of the effective date no more new series will be introduced. Series without open interest will be deleted.
- As soon as there are no more series with open positions trading will be put on “Halt” and finally discontinued.

Futures

- As of the effective day, the Novartis-Future single stock future reflects a basket containing one Novartis-share and a number of Alcon-shares, which reflects the subscription ratio.
- For the contract to be settled in cash, the adjustment will be made via the daily closing price.
- No new contract months will be introduced in the original contracts NOVF/N2OV.
- As of the effective day, the Novartis-Dividend Future contract reflects a basket containing one Novartis-share and the dividend of a number of Alcon-shares, which reflects the subscription ratio.
- As of the effective date no more new expiration months will be introduced. Series without open interest will be deleted.
- The ISIN and the name of the current Novartis-Futures will change in Eurex Exchange`s T7. Details will follow in good time.